Mineralys Therapeutics (MLYS) EBITDA Margin (2023 - 2026)
Mineralys Therapeutics (MLYS) reported EBITDA Margin of -4964.39% for Q2 2026, down 3619.25 percentage points from -1345.14% a year earlier and down 4208.32 percentage points from the prior quarter.
Mineralys Therapeutics (MLYS) EBITDA Margin (2023 - 2026) Analysis & Trends
Over the twelve months ended Jun 30, 2026, Mineralys Therapeutics' EBITDA Margin came in at -1749.49%, down 98.47 percentage points year-over-year; for FY2025, it came in at -1069.05%, up 249.57 percentage points from FY2024.
- By year, EBITDA Margin came in at -1318.62% in FY2024 (-654.95 pp) and -663.66% in FY2023.
- The Q2 2026 figure ranks as the lowest quarterly EBITDA Margin in data going back to Q1 2023.
- Year over year, EBITDA Margin gained in three of the last eight quarters, with an average year-over-year change of -468.26 percentage points.
- The high point for year-over-year EBITDA Margin in five years was Q1 2026 (a gain of 1228.39 percentage points); the low point was Q2 2026 (a drop of 3619.25 percentage points).
- Per Business Quant data, the three quarters before Q2 2026 came in at -756.07% (Q1 2026), -633.04% (Q4 2025) and -980.12% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,264.65 Bn | 1,238.27 Bn | 20.46 Bn | 54.65% |
| 2 | Johnson & Johnson | 677.74 Bn | 597.60 Bn | 17.30 Bn | 32.68% |
| 3 | AbbVie | 517.10 Bn | 485.11 Bn | 13.12 Bn | 46.88% |
| 4 | Merck | 362.23 Bn | 325.17 Bn | 13.19 Bn | 40.75% |
| 5 | Novartis Ag | 315.90 Bn | 276.16 Bn | 11.24 Bn | - |
| 6 | Astrazeneca | 289.40 Bn | 266.24 Bn | 12.86 Bn | - |
| 7 | Amgen | 249.90 Bn | 201.56 Bn | 7.58 Bn | 46.62% |
| 8 | Gilead Sciences | 209.15 Bn | 184.26 Bn | 6.73 Bn | 50.63% |
| 9 | Pfizer | 165.88 Bn | 113.23 Bn | 12.56 Bn | 42.49% |
| 10 | Mineralys Therapeutics | 1.42 Bn | -1.17 Bn | - | - |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -4,964.39% |
| Mar 31, 2026 | -756.07% |
| Dec 31, 2025 | -633.04% |
| Sep 30, 2025 | -980.12% |
| Jun 30, 2025 | -1,345.14% |
| Mar 31, 2025 | -1,984.46% |
| Dec 31, 2024 | -1,842.36% |
| Sep 30, 2024 | -1,592.34% |
| Jun 30, 2024 | -1,087.64% |
| Mar 31, 2024 | -917.57% |
| Dec 31, 2023 | -834.42% |
| Sep 30, 2023 | -747.88% |
| Jun 30, 2023 | -437.93% |
| Mar 31, 2023 | -641.39% |
Mineralys Therapeutics EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=MLYS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "MLYS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=MLYS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();